Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy
Authors' conclusion
Actual body weight and RRT intensity and duration are the main determinants of vancomycin dosing requirements in critically ill patients treated with RRT.
Study context
- Population
- Critically ill patients treated with vancomycin and various renal replacement therapy (RRT) modalities
- Participants
- 65 patients · 6 countries
- Outcome
- Probability of dosing regimens achieving the MRSA efficacy target (AUC0-24 h/MIC ≥ 400) without exceeding the toxicity threshold (AUC0-24 h ≥ 700 mg.h/L)
Methodological detailsprospective, international, external validation, Monte Carlo dosing simulations
- Prospective
- International
- External validation
- Monte Carlo dosing simulations
Performance
As reported in the abstract
- Dosing requirements dependent on actual body weight and RRT intensity and duration
- p < 0.05
- Model predictive performance high (median prediction error)
- −13.4%
Further findings
RRT modality of enrolled patients
- Continuous RRT
- 50.8%
- Sustained low-efficiency dialysis
- 49.2%
External validation dataset
- Critically ill patients
- 19
- Pre-filter plasma concentrations
- 124
- Concomitant ECMO
- 47.4%
- Model developed using 1318 pre- and post-filter plasma and effluent concentrations
Original publication
Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy. Crit Care. Published 4 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →